Related references
Note: Only part of the references are listed.Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
S. P. Rajeev et al.
DIABETES OBESITY & METABOLISM (2016)
Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters
Masato Furuhashi et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension
Masato Furuhashi et al.
HYPERTENSION RESEARCH (2015)
SGLT2 Inhibitors May Predispose to Ketoacidosis
Simeon I. Taylor et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus
Masato Furuhashi et al.
JOURNAL OF LIPID RESEARCH (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity
Meric Erikci Ertunc et al.
JOURNAL OF LIPID RESEARCH (2015)
FABP4 is Secreted from Adipocytes by Adenyl Cyclase-PKA- and Guanylyl Cyclase-PKG-Dependent Lipolytic Mechanisms
Tomohiro Mita et al.
OBESITY (2015)
Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population
Takahiro Fuseya et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Adipocyte Lipid Chaperone aP2 Is a Secreted Adipokine Regulating Hepatic Glucose Production
Haiming Cao et al.
CELL METABOLISM (2013)
Circulating Levels of Fatty Acid-Binding Protein Family and Metabolic Phenotype in the General Population
Shutaro Ishimura et al.
PLOS ONE (2013)
Elevation of Fatty Acid-Binding Protein 4 Is Predisposed by Family History of Hypertension and Contributes to Blood Pressure Elevation
Hideki Ota et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease A 10-year Prospective Study
Maximilian von Eynatten et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients
Toru Miyoshi et al.
HEART AND VESSELS (2011)
Serum Fatty Acid-Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease
Masato Furuhashi et al.
PLOS ONE (2011)
Lipid Chaperones and Metabolic Inflammation
Masato Furuhashi et al.
INTERNATIONAL JOURNAL OF INFLAMMATION (2011)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes
Anna Cabre et al.
JOURNAL OF LIPID RESEARCH (2008)
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Masato Furuhashi et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria
Anna Cabre et al.
CLINICAL CHEMISTRY (2008)
Serum adipocyte fatty acid-binding protein as a new biomarker, predicting the development of type 2 diabetes - A 10-year prospective study in a Chinese cohort
Annette W. K. Tso et al.
DIABETES CARE (2007)
Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis
D. C. Y. Yeung et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia
M. Karpisek et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
Masato Furuhashi et al.
NATURE (2007)
Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome - A 5-year prospective study
Aimin Xu et al.
CIRCULATION (2007)
Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome
AM Xu et al.
CLINICAL CHEMISTRY (2006)
Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis
L Makowski et al.
NATURE MEDICINE (2001)
Share Paper
